share_log

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30

Wedbush维持Denali Therapeutics的跑赢大盘,将目标股价下调至30美元
Benzinga ·  05/08 10:20

Wedbush analyst Laura Chico maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and lowers the price target from $31 to $30.

Wedbush分析师劳拉·奇科维持Denali Therapeutics(纳斯达克股票代码:DNLI)的表现跑赢大盘,并将目标股价从31美元下调至30美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发